Overview

Hospital Avoidance Strategies for ABSSSI

Status:
Terminated
Trial end date:
2021-10-14
Target enrollment:
Participant gender:
Summary
More than 40% of patients presenting with acute bacterial skin and skin structure infection (ABSSSI) to the Barnes-Jewish Hospital (BJH) emergency department (ED) are admitted for intravenous antibiotics. There is growing evidence to suggest that many hospital admissions for uncomplicated ABSSSI due to Gram-positive bacteria could be avoided with an alternative treatment strategy employing newer long-acting antibiotics. Coupled with close outpatient follow-up, such an alternative hospital avoidance strategy has the potential to improve quality and value of care for patients with uncomplicated ABSSSI and optimize use of limited inpatient healthcare resources.
Phase:
Phase 4
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Allergan
The Foundation for Barnes-Jewish Hospital
Treatments:
Dalbavancin